Comparative Pharmacology
Head-to-head clinical analysis: MAXZIDE versus ORETICYL 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXZIDE versus ORETICYL 50.
MAXZIDE vs ORETICYL 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Maxzide is a combination of triamterene, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal renal tubule, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule. The combination reduces electrolyte disturbances.
Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing diuresis.
Hydrochlorothiazide 25 mg / triamterene 37.5 mg orally once daily; may increase to twice daily if needed. Max dose: hydrochlorothiazide 50 mg / triamterene 75 mg daily.
Hydrochlorothiazide 50 mg orally once daily in the morning; may increase to 100 mg daily in divided doses.
None Documented
None Documented
Triamterene: terminal half-life is approximately 4-6 hours in healthy individuals, but may be prolonged in renal impairment. Hydrochlorothiazide: terminal half-life is approximately 6-15 hours, and it accumulates in renal dysfunction. The combination product's effective half-life is influenced by both components.
Terminal elimination half-life: 6–15 hours (mean 10 hours), prolonged in renal impairment (up to 24–30 hours) and elderly.
Renal: triamterene and hydrochlorothiazide are primarily excreted by the kidneys. Triamterene is extensively metabolized; about 20-30% of the dose is excreted unchanged in urine, with additional metabolites. Hydrochlorothiazide is excreted unchanged in urine (at least 61% of an oral dose within 24 hours).
Renal: ~95% (50% as unchanged drug, remainder as inactive metabolites); Biliary/fecal: <5%.
Category C
Category C
Diuretic Combination
Diuretic Combination